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ABSTRACT
Background
Ebola virus causes a hemorrhagic fever syndrome that is associated with high mortality in
humans. In the absence of effective therapies for Ebola virus infection, the development of a
vaccine becomes an important strategy to contain outbreaks. Immunization with DNA and/or
replication-defective adenoviral vectors (rAd) encoding the Ebola glycoprotein (GP) and
nucleoprotein (NP) has been previously shown to confer specific protective immunity in
nonhuman primates. GP can exert cytopathic effects on transfected cells in vitro, and multiple
GP forms have been identified in nature, raising the question of which would be optimal for a
human vaccine.
Methods and Findings
To address this question, we have explored the efficacy of mutant GPs from multiple Ebola
virus strains with reduced in vitro cytopathicity and analyzed their protective effects in the
primate challenge model, with or without NP. Deletion of the GP transmembrane domain
eliminated in vitro cytopathicity but reduced its protective efficacy by at least one order of
magnitude. In contrast, a point mutation was identified that abolished this cytopathicity but
retained immunogenicity and conferred immune protection in the absence of NP. The minimal
effective rAd dose was established at 10
10 particles, two logs lower than that used previously.
Conclusions
Expression of specific GPs alone vectored by rAd are sufficient to confer protection against
lethal challenge in a relevant nonhuman primate model. Elimination of NP from the vaccine
and dose reductions to 10
10 rAd particles do not diminish protection and simplify the vaccine,
providing the basis for selection of a human vaccine candidate.
The Editors’ Summary of this article follows the references.
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Epidemics of Ebola virus hemorrhagic fever result in a fatal
illness in the majority of patients who become infected, with
case-fatality rates nearing 90%. Studies of patients who
survive infection indicate that components of the adaptive
immune system are activated in infected survivors [1],
suggesting that vaccination of target populations could
signiﬁcantly reduce mortality from exposure to Ebola virus.
We previously described a vaccine that elicits strong adaptive
immune responses and uniformly protects nonhuman pri-
mates from a high-dose challenge with Zaire ebolavirus
(ZEBOV) [2,3]. A single immunization with vectors derived
from adenovirus type 5 (5 Ad5) containing Ebola glycopro-
tein (GP) and nucleoprotein (NP) genes elicited protective
immune responses within 1 mo. The strength of rAd5 vectors
for use as vaccines derives from their ability to elicit rapid
immunity due to high insert expression levels and natural
targeting of Ad5 to dendritic cells, which may enhance
antigen presentation. Moreover, the use of replication-
defective viral vectors for gene delivery is desirable from a
safety perspective for products that will be developed for
human use.
Beyond considerations of vector choice, selection of the
target viral antigen(s) must incorporate determination of
relative magnitudes of protective immunity elicited by
different inserts, and breadth of protection across virus
subtypes. Ebola virus comprises four species, ZEBOV, Sudan
ebolavirus (SEBOV), Ivory Coast, and Reston, with ZEBOV
and SEBOV contributing the highest mortality in natural
outbreaks. Therefore, the Zaire and Sudan (Gulu) ebolavi-
ruses were selected for studies in which we sought to provide a
basis for selection of a human vaccine candidate by identify-
ing the optimal vaccine composition with respect to antigen
strength and immune protection in nonhuman primates.
Ebola NP was included in the vaccine because it is highly
conserved among Ebola subtypes and has been found to elicit
strong cellular immune responses in animal models [4,5].
Methods
Vector Construction and Transfections
The reagents used in this study were produced by Crucell
(Leiden, Netherlands) following the Organization for Eco-
nomic Cooperation and Development Principles of Good
Laboratory Practice as guidance, and using methods similar
to and designed for easy scale-up to GMP clinical-grade
preparation. The GP point mutant vectors are currently in
preparation for clinical trials. E1/E3-deleted, replication-
incompetent Ad5 vectors were generated in PER.C6 cells [6]
using a pBR322-based adaptor plasmid pAdApt together with
the cosmid pWE.Ad.AﬂlII-rITRDE3, essentially as described
elsewhere [7]. The adaptor plasmid contained the left portion
of the Ad5 genome (nucleotides 1–454), followed by tran-
scriptional control elements and the adaptor Ad5 DNA
region (nucleotides 3511–6095 in Ad5). Ebola GP-encoding
genes were cloned into the expression cassette in the adaptor
plasmids under transcriptional control of the human full-
length immediate-early CMV promoter and the SV40 poly-
adenylation signal.
Adenoviruses containing Ebola GP, GPDTM, and point
mutations were generated by cotransfection of linearized
pAdApt-Ebola GP plasmids together with the linearized
cosmid pWE.Ad.AﬂlII-rITRDE3 containing the right portion
of the Ad5 genome to PER.C6 cells using Lipofectamine
(Invitrogen, Carlsbad, California, United States). PER.C6 cells
were cultured in DMEM supplemented with 10% fetal bovine
serum (GIBCO, San Diego, California, United States) and
incubated at 37 8C in a humidiﬁed atmosphere at 10% CO2.
Homologous recombination led to the generation of rAd5-
Ebola GP viruses. Adenoviral vectors in crude lysates were
plaque-puriﬁed using limiting dilutions and agar overlays,
and Ad vector clones were analyzed for presence and
expression of the transgene. Positive clones were ampliﬁed
for large-scale production using PER.C6 cells in 48 triple-
layer 3 3 175 cm
2 ﬂasks. Viruses were puriﬁed by standard
two-step CsCl gradient ultracentrifugation and subsequently
desalted and formulated by three consecutive dialysis steps
into Tris-HCl (pH 8.0) containing 2.5% glycerol. Puriﬁed Ad
vectors were stored as single use aliquots at  80 8C. Virus
particle titers were determined by anion-exchange HPLC
based on described procedures [8]. Infectivity was assessed by
TCID50 using 911 cells [9].
Adenovirus-mediated Ebola GP expression was assessed by
infection of A549 cells followed by analysis of culture lysates
on Western blot. The identity of the puriﬁed vectors was
conﬁrmed by PCR.
Expression vectors p1012, pGP, and pDTM and point
mutants contain a CMV enhancer promoter that has been
described [2,10]. The pDTM contains a deletion from amino
acids 651 to 676 and was created by digesting with BspMI/
Klenow, and then fusing to TGA. The resulting plasmid also
contained four extra amino acids (aa) at the C terminus
(MAAS). HEK293 cells and the derivative T-Ag-expressing
293T cell line were cultured in DMEM supplemented with
10% fetal bovine serum (GIBCO). Transfections to measure
protein expression and cell rounding were performed in
HEK293 cells with 2 lg of DNA per well of a six-well plate
using calcium phosphate (Invitrogen) according to the
manufacturer’s instructions. Protein expression in cell super-
natants or lysates was evaluated by SDS-PAGE followed by
Western blot with a GP-speciﬁc polyclonal antibody kindly
provided by A. Sanchez (Centers for Disease Control, Atlanta,
Georgia, United States). Comparison of secreted and cellular
expression levels was measured from 0.6% and 1%, respec-
tively, of total sample volumes.
Animal Study and Safety
Cynomolgus macaques (Macaca fascicularis), aged 3–5 y and
weighing 2–3 kg, obtained from Covance (Princeton, New
Jersey, United States), were used for immunization and
challenge experiments. Each treatment group contained
three animals unless stated otherwise. To prevent unneces-
sary use of animals, only one unvaccinated control was
included in each study, but cumulatively over the study
period, there were 29 such controls using the same virus seed
stock, administered by the same route at the same dose, lethal
for all animals with a mean time to death of 6.4 d. The
monkeys, housed singly, were anesthetized with ketamine to
obtain blood specimens and to administer vaccines. In
conducting this research, the investigators adhered to the
1996 version of the animal care and usage guide prepared by
the Institute of Laboratory Animal Resources [11]. The
facilities are fully accredited by the Association for Assess-
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tional and the animals received regular enrichment. Before
Ebola virus challenge and to the end of each experiment, the
animals were maintained in the Maximum Containment
Laboratory (BSL-4) and fed and checked daily.
Macaque Immunization and Challenge
Cynomolgus macaques were injected intramuscularly with
1.0 ml of an equal mixture of immunogens at the doses
indicated. Viral challenge was performed by inoculation of
animals in the left or right caudal thigh with 0.5 ml of viral
stock that contained a target dose of ;1,000 plaque-forming
units (pfu) ZEBOV at 4 wk after the initial immunization. No
adverse effects of the adenovirus vaccination were observed
acutely. The Ebola virus stock used in this study was originally
obtained from a fatally infected human from the former
Zaire in 1995 [12]. Collection of serum and blood for viral
load and ELISA titers was performed as previously described
[2]. Surviving animals were followed for at least 4 wk
postchallenge.
Flow Cytometry and Antibodies
Transfected cells were collected after incubation with PBS
containing 3 mM EDTA and incubated with control Ig or
rabbit anti-sGP/GP serum (generously provided by Dr. A.
Sanchez, CDC) for 30 min on ice. The cells were washed twice
with ice-cold PBS containing 2.5% fetal bovine serum,
incubated with FITC- or PE-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grove, Penn-
sylvania, United States; and Sigma-Aldrich, St. Louis, Missou-
ri, United States, respectively) for 30 min on ice, followed by
washing. Analysis was conducted using a Becton-Dickinson
four-color Calibur ﬂow cytometer and FlowJo analysis
software (Tree Star, Ashland, Oregon, United States).
ELISA
Nunc-Immuno Maxisorp plates (Nunc, Rochester, New
York, United States) were coated with 100 ll/well of 10 lg/
ml lectin from Galanthus nivalis (Sigma-Aldrich) in PBS and
incubated overnight at 4 8C. All further incubations were
carried out at room temperature. Plates were then blocked
for 2 h in PBS containing 10% fetal calf serum and then
washed twice with 0.2% Tween 20 (Sigma-Aldrich) in PBS.
Ebola GP was obtained from the supernatants of HEK293
cells transfected with the mammalian expression plasmid
Ebola GP(DTM) and was added to the plates at a concen-
tration of 0.8–1.3 mg/ml total protein in 100 ll/well. Plates
were then washed six times with PBS containing 0.2% Tween
20. Test sera were diluted in PBS containing 0.2% Tween 20
and 1% fetal calf serum and allowed to react with the Ag-
coated wells for 60 min. After washing plates six times, goat
anti-human IgG (HþL; Chemicon, Temecula, California,
United States) conjugated to horseradish peroxidase was
used as a detection antibody. Bound IgG was detected by
Sigma Fast O-phenylenediamine dihydrochloride tablet sets
(Sigma-Aldrich), and the optical density was determined. A
panel of normal sera was run each time the assay was
performed.
Neutralizing Antibody Analysis
Ebola GP(Z) pseudotyped lentiviral virions were produced
as previously described [13]. Brieﬂy, 293T cells were plated at
a density of 2 3 10
6 per 10-cm diameter tissue culture dish
and transfected the next day by calcium phosphate reagent
(Invitrogen) with pCMVDR8.2, pHR9CMV-Luc, and CMV/R
Ebola GP(Z) plasmid DNA. Cells were transfected overnight,
washed, and replenished with fresh medium. Supernatants
containing pseudotyped virus were harvested 48 h later,
ﬁltered through a 0.45-lm pore-size syringe ﬁlter, and stored
in aliquots at  80 8C. Neutralization assays were performed
on HUVECs (Cambrex, East Rutherford, New Jersey, United
States; #CC-2517) plated in a 24-well plate 1 d prior to
infection. Virus stocks titrated to the 90% infectious dose
were incubated at 37 8C for 1 h in the presence of serum from
immunized cynomolgus macaques. The culture media was
removed from the cells and replaced with the virus/serum
Figure 1. Elimination of GP Cytopathic Effects and Expression of Transmembrane-Deleted Protein
(A) Expression of GP(DTM) in HEK293 cells. Ebola GP proteins from supernatants and cell lysates were visualized by SDS-PAGE and Western blot using a
polyclonal antibody against Ebola GP.
(B) Elimination of cell rounding by GPDTM. HEK293 cells were transfected with a plasmid that encoded vector control, Ebola GP, or Ebola GPDTM. Cell
monolayers were visualized under phase contrast using a Nikon 403 objective and photographed at 24 h posttransfection.
DOI: 10.1371/journal.pmed.0030177.g001
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at a ﬁnal concentration of 5 lg/ml. At 72 h postinfection, cells
were lysed and assayed by the Luciferase Assay System
(Promega, Madison, Wisconsin, United States; #E1501/
E1531). Luciferase activity was determined using a Veritas
Microplate Luminometer from Turner Biosystems (Sunny-
vale, California, United States).
Intracellular Cytokine Analysis
Peripheral blood mononuclear cells were isolated from
cynomolgus macaque whole blood samples by separation
over Ficoll. Approximately 1 3 10
6 cells were stimulated in
200 ll of RPMI medium (GIBCO) for 6 h at 37 8C with anti-
CD28 and anti-CD49d antibodies [14], brefeldin A, and either
DMSO or a pool of 15-mer peptides spanning the ZEBOV GP
(Mayinga strain) open reading frame of the full length virion-
bound form. There was a total of 167 15-mers overlapping by
11 spanning the entire Ebola glycoprotein at a ﬁnal
concentration of 2.5 lg/ml. Cells were ﬁxed and permeabi-
lized with FACS Lyse (Becton Dickinson, Palo Alto, Cal-
ifornia, United States) supplemented with 0.05% Tween 20,
and stained with a mixture of ﬂuorescence-conjugated
antibodies against lineage markers (CD3, CD4, CD8) and
TNF. Samples were run on a FACS Calibur or FACS Aria
ﬂow cytometer and analyzed using the software, FlowJo.
Positive gating for lymphocytes using forward versus side
scatter was followed by CD3
þ/CD8
  and CD3
þ/CD4
  gating,
and speciﬁc populations were further deﬁned by anti-CD4
and anti-CD8 positivity, respectively. Cytokine-positive cells
were deﬁned as a percentage within these individual
lymphocyte subsets and at least 200,000 events were analyzed
for each sample.
Results
To develop an optimal Ebola vaccine using rAd vectors,
we ﬁrst analyzed mutant forms of GP in which the
transmembrane domain had been removed. Although we
have previously reported that deletion of the mucin domain
eliminates cytotoxicity [15], this deletion removes nearly 200
aa, eliminating many potential T and B cell epitopes.
Previous data suggested that the in vitro cytopathic effects
of GP may be mediated at or near the cell surface and
require transmembrane anchoring of the protein [16–18].
An alternative approach to the elimination of the GP-
induced cytopathic effects was therefore explored by
removal of the 26 aa putative transmembrane and cytoplas-
mic domains.
Diminished Immune Protection of a Mutant GP Lacking a
Transmembrane Anchor Domain
GP protein was readily detected in the supernatants of cells
transfected with the transmembrane-deleted vector DTM(Z),
conﬁrming its secretion, in contrast to supernatants from
cells transfected with the wild-type GP(Z) (Figure 1A).
Furthermore, synthesis of the two previously deﬁned forms
of GP, generated by posttranslational processing [19,20], was
readily detected at comparable levels. Deletion of the trans-
membrane domain eliminated GP-induced cytopathicity in
transfected HEK293 cells in contrast to wild-type GP (Figure
1B), but total DTM expression was equivalent to wild-type
protein levels (Figure 1A). To determine whether the DTM
mutant of the ZEBOV could protect against infectious Ebola
challenge, cynomolgus macaques were immunized with rAd
vectors encoding NP and either DTM(Z) or GP(Z). Immuniza-
tion with GP(Z) þ NP protected all animals vaccinated with
either 10
11 or 10
12 adenoviral particles and challenged with
1,000 pfu of ZEBOV 28 d later (Figure 2A). In contrast,
survival frequencies decreased in animals receiving the
DTM(Z) vaccine. In the group vaccinated with 10
12 adenoviral
particles, protective immunity was decreased by 33% and, at
10
11, by 66%, indicating a substantial decrease in efﬁcacy in
animals vaccinated with DTMþNP versus GPþNP (p , 0.05).
In a separate experiment (unpublished data), 10
11 particles of
DTM alone failed to protect against infection. Analysis of cell-
mediated immune responses showed that GP-speciﬁc CD4
þ
and CD8
þ T-cell responses were present in the majority of
animals by 3 wk postimmunization (Figure 2B, left and middle
panels, respectively) and correlated well with NP-speciﬁc
Figure 2. Comparative Efficacy of GP and GPDTM for Protection against
Ebola Virus Challenge
(A) Kaplan-Meier survival curve of cynomolgus macaques, immunized as
indicated, and challenged with 1,000 pfu of Zaire ebolavirus (strain
Kikwit) 1 mo post immunization. The x-axis indicates weeks post-
challenge. Different immunization groups had n¼3, except for the GP(Z)
þ NP (10
12) group (n ¼ 4), and control (n ¼ 1).
(B) Immune responses in immunized animals. Left and middle graphs:
Intracellular flow cytometry was performed to quantify TNF-a production
from Ebola-specific CD4
þ or CD8
þ lymphocytes, respectively, from
animals immunized as indicated (the 1012 group contains only three
CD8 points due to technical error in one sample). Immune responses
were measured at 3 wk postimmunization. Circles, diamonds, squares,
and triangles indicate responses for individual animals. Horizontal line
indicates the average of individual responses in the immunization group.
Results represent the percent cytokine-positive in the gated lymphocyte
group, and background stimulation (DMSO alone) has been subtracted
from each sample. ELISA titers of Ebola GP-specific antibodies in sera of
vaccinated animals collected at week 3 postimmunization (right graph).
ELISA results represent endpoint dilution titers determined by optical
density as described in Methods.
DOI: 10.1371/journal.pmed.0030177.g002
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lar responses measured by intracellular cytokine (tumor
necrosis factor-a [TNF-a]) secretion were indistinguishable
between GP(Z)- and DTM(Z)-vaccinated animals. Similarly,
humoral immune responses measured by anti-Ebola GP
ELISA IgG titers were comparable in all vaccinated animals
(Figure 2B, right graph). Neutralizing antibody titers were
low, and were absent in some surviving animals (unpublished
data). These results suggested that deletion of the GP
transmembrane domain reduces vaccine efﬁcacy, with no
readily apparent correlates of protection.
Definition of Minimal Protective Vaccine Dose for
Protection with a rAd Vaccine Encoding GP and NP
In the previous experiment, a log decrease in dose of the
GP(Z)þNP vaccine was protective, in comparison to previous
studies using 10
12 rAd particles. To establish the lowest dose
of adenoviral vectors that would afford protection against
Ebola infection, a dose-response analysis was performed.
Animals were immunized with rAd vectors encoding GP(Z)
and NP at increasing doses from 10
9 to 10
12 particles per
animal. Survival was 100% in all groups receiving a dose of
10
10 or greater, whereas challenge infection was uniformly
lethal in the 10
9 dose group (Figure 3A). Ebola virus isolation
from plasma by plaque assay on Vero cells was negative for all
surviving animals (unpublished data). Plasma could in theory
contain factors such as immunoglobulin or cytokines that
could impede virus replication. While other methods, such as
RT-PCR, could potentially be used to detect such virus, a
negative signal with this assay is not conclusive of sterilizing
immunity, and no clear correlation between viremia and
mortality has been established in nonhuman primate models
of Ebola virus infection. Survival was therefore used as the
study endpoint in these experiments. Prechallenge CD4
þ T
cell responses for TNF-a were unremarkable, as reported
previously for immunized cynomolgus macaques (Figure 3B).
CD8
þ T cell responses were similar across vaccine dose
groups, except for the higher responder immunized at 10
12
rAd particles. Antigen-speciﬁc IgG was also generated in
immunized animals, and the levels were equivalent among
animals in the groups that survived Ebola virus challenge
(Figure 3C, left graph). However, there was a difference of
more than one log (p ¼0.004) in IgG levels between survivors
immunized at 10
10 particles (9,600 6 6,000) and fatalities
immunized at 10
9 rAd particles (600 6 300), suggesting that
such levels may correlate with protection for this immuniza-
tion regimen. In contrast, neutralizing antibody titers against
GP did not differ signiﬁcantly between survivors and fatalities
(Figure 3C, right graph), suggesting that ELISA IgG titers may
be a stronger predictor of protective immunity for this
vaccine. These results indicated that the threshold for
immune protection lies at about 10
10 rAd particles. There-
fore, subsequent experiments were carried out using this dose
to increase sensitivity to detect differences in antigenic
strength between various immunogens.
Identification of a GP Point Mutant with Diminished In
Vitro Cytotoxicity That Confers Effective Immune
Protection
We sought to identify other mutants of GP that do not
exhibit cytopathic effects yet retain native antigenic struc-
tures when expressed in vitro. Relatively conserved regions of
Figure 3. Determination of Lowest Vaccine Dose for Immune Protection
against Ebola Virus Challenge by Adenoviral Vector GP/NP Vaccine
(A) Kaplan-Meier survival curve of macaques: Immunization was with rAd
vectors expressing GP(Z) and NP(Z) (109–1011, three animals per group;
control and 10
12, one animal each), and challenge was performed with
the Kikwit strain of Zaire ebolavirus as in Figure 2A.
(B) Immune responses in immunized animals. Intracellular flow cytometry
was performed to quantify TNF-a production from Ebola-specific CD4
þ
(left graph) or CD8
þ (right graph) lymphocytes, respectively, from
animals immunized as indicated. Immune responses were measured at 3
wk postimmunization. Circles, diamonds, and squares indicate responses
for individual animals. Horizontal line indicates the average of individual
responses in the immunization group. Results represent the percent
cytokine positive in the gated lymphocyte group and background
stimulation (DMSO alone) has been subtracted from each sample (p-
values obtained using unpaired Student’s t-test; n.s., not significant).
(C) Antibody responses in immunized animals. Anti-GP ELISA titers (left
graph) and serum neutralizing antibody responses (right graph) were
measured as described in Methods.
DOI: 10.1371/journal.pmed.0030177.g003
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introduced. GP proteins bearing single-amino acid changes
were screened for decreased induction of cell rounding but
wild-type levels of expression and reactivity with conforma-
tion-dependent antibodies. Substitution of aspartic for
glutamic acid at position 71 (i.e., E71D) in Ebola GP from
the Zaire or Sudan/Gulu species (E71D[Z] or E71D[S/G],
respectively) abolished the cell-rounding phenotype in trans-
fected HEK293 cells, but did not alter protein expression or
reactivity with antibodies whose binding properties are
sensitive to changes in protein conformation (Figure 4).
The E71D mutants were evaluated for their ability to induce
protective immunity alone or in combination with NP,
compared with the wild-type GP/NP immunogen. When
E71D from Zaire and Sudan/Gulu were combined with NP,
survival of cynomolgus macaques immunized in these groups
was diminished by 33% and 66%, respectively (Figure 5A). In
contrast, complete protection was achieved in animals immu-
nized with E71D(Z) and E71D(S/G), as it was in animals
receiving wild-type GP(Z)þNP. Ebola GP-speciﬁc responses in
T lymphocytes detected by intracellular staining of TNF-a did
not show statistically signiﬁcant differences in the CD4
þ
population between different immunization groups (Figure
5B, left graph). Similarly, individual differences in the CD8
þ
response did not correlate with survival, although there was a
trend toward diminished survival in groups with lower
antigen-speciﬁc CD8
þ cellular responses (Figure 5B, middle
graph).Antigen-speciﬁcELISAIgG,whichcorrelatedwellwith
survival in the dose-ranging experiment, was also stimulated
in all immunized animals (Figure 5B, right graph). The results
of this experiment illustrate that NP may not be necessary for
protective immunity against Ebola infection and that it may
diminish protection when combined with modiﬁed GP
immunogens at the lower limits of protective vaccine doses.
Discussion
Ebola virus outbreaks are associated with high lethality due
to the absence of treatment options or a licensed vaccine.
Both DNA priming with rAd vector boosting and rAd alone
can confer protection to lethal challenge in an animal model
that closely parallels human disease [21]. The rAd vector
vaccine conferred protection in an accelerated vaccine
regimen in a nonhuman primate species [3]. Although in
vitro cytopathicity has been observed by overexpression of
Ebola GP (one of the vaccine components), we have not seen
toxicity in animals vaccinated by vectors expressing Ebola GP
(unpublished data). However, because this hypothetical
complication has been raised, we sought to modify GP to
eliminate in vitro cytopathicity yet retain antigenic proper-
ties that are necessary for protective immunity. Here, the
efﬁcacies of different forms of GP were evaluated using doses
at the threshold of protection in the accelerated vaccination
model. We have identiﬁed a vaccine with decreased in vitro
cytopathicity that retained immunogenicity necessary to
protect against Ebola infection.
We ﬁnd that alternative forms of GP confer differential
immune protection. Deletion of the GP transmembrane
domain abolished cytopathic effects in transfected HEK293
cells, but the corresponding DTM(Z) vaccine was less efﬁca-
cious than wild-type GP(Z) in protecting the cynomolgus
macaques against infection. Although cellular and humoral
immune responses were indistinguishable between groups
receiving the different immunogen forms, the inherent
variability in quantitating the responses in outbred macaques
may obscure our ability to identify immune responses
responsible for higher survival. Alternatively, DTM(Z) may
differ from wild-type GP(Z) in antigenic qualities that are not
captured by measurements of total antigen-speciﬁc IgG or
intracellular cytokine responses stimulated by a broad
Figure 4. Elimination of GP Cytopathic Effects with Single Point Mutation
(A) Expression of point mutants in HEK293 cells. Ebola GP proteins from supernatants and cell lysates were visualized by SDS-PAGE and Western blot
using a polyclonal antibody against Ebola GP.
(B) Reactivity of point mutants with a conformation-dependent antibody. HEK293 cells were transfected with a control plasmid (red line) or plasmids
expressing wild-type (GP[Z], blue line), or mutant (E71D[Z], green line) proteins. 18 h posttransfection, cells were harvested and stained with a GP-
specific antibody, and cell surface GP expression was analyzed by flow cytometry.
(C) Elimination of cell rounding by amino acid substitution at position 71. HEK293 cells were transfected with a plasmid that encoded vector control,
wild-type Ebola glycoprotein from Zaire (GP[Z]) or Sudan/Gulu (GP[S/G]), or their respective point mutations (E71D[Z] and E71D[S/G]). Cell monolayers
were visualized under phase contrast using a Nikon 403 objective and photographed at 24 h posttransfection.
DOI: 10.1371/journal.pmed.0030177.g004
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protein is secreted and likely shows conformational differ-
ences from the membrane-anchored protein. Subsequent
modiﬁcations of the glycoprotein to retain membrane
attachment and a more native envelope structure yielded a
mutant, E71D, with reduced in vitro cytopathicity. Recently,
it was suggested that this region of GP contributes to viral
receptor binding [22]. It is noteworthy that the envelope
glycoprotein cytopathicity of other viruses such as HIV is
linked to receptor binding and fusion [23], raising the
possibility that Ebola GP shares similar properties.
Ongoing outbreaks of both Ebola and Marburg viruses
illustrate the importance of developing a ﬁlovirus vaccine for
human use. This report shows that protective immunity
against Ebola infection is achieved in nonhuman primates by
the generation of antigen-speciﬁc immune responses to a
single protein, GP, which has been modiﬁed to eliminate in
vitro cytopathic effects. Since the vaccine will be licensed
initially against one agent, protective immunity was evaluated
against challenge with this species, Zaire ebolavirus. Future
studies will address whether this vaccine can protect against
other Ebola species, such as SEBOV. Preliminary studies
suggest that protection can be observed in animals receiving
the bivalent vaccine that survive ZEBOV challenge when
subsequently exposed to the Gulu strain of SEBOV (unpub-
lished data). However, complete analysis of the question of
cross-strain protection will require additional studies that fall
beyond the scope of the present study.
In a dose-ranging experiment with rAd expressing GP and
NP, immune protection correlated well with GP-speciﬁc
ELISA IgG titers. This observation is consistent with early
Ebola vaccine studies performed using a gene-based GP and
NP vaccine in guinea pigs. In the current study there was also
a trend toward increased survival in animals with higher
CD8
þ T cell responses when vaccines containing different
antigen combinations were evaluated for protective efﬁcacy.
In combination, these ﬁndings suggest that the GP-speciﬁc
humoral immune response provides a correlate of immunity;
however, it is likely that the T cell response contributes to
protection, and the Ig response may be a reﬂection of T cell
help. Further improvements in the sensitivity of the T cell
assay, as well as immune depletion studies, may provide
further insight into this question.
Ebola virus protective immunity has also been achieved
more recently using replication competent vesicular stoma-
titis virus vectors [24], supporting the concept that vacci-
nation for Ebola can successfully protect against disease
mortality. While this vaccine merits further investigation, and
replication-competent viruses have contributed to many
effective vaccines, concerns remain about live viruses because
the amount of viral replication cannot be controlled, and
their environmental effects are uncertain. Such consider-
ations may pose challenges to development of vesicular
stomatitis virus-based vaccines for human use. The recent
recommendation that the live-attenuated polio vaccine, a
relatively safe vaccine, no longer be used in the United States
[25], and the inactivated virus be used instead, exempliﬁes
these challenges. In contrast, the rAd vector vaccine is
nonreplicating and can be manufactured to high yields, and
safety data exist for this platform. Here we show that
immunity follows a single injection with 10
10 rAd particles,
a dose that is two orders of magnitude lower than previously
reported for this single-modality vaccine. Such doses of rAd
vectors have proved to be well tolerated and immunogenic
for other recombinant genes in vivo and can be evaluated for
the vectors reported here, alone or in DNA prime/rAd boost
combinations. One theoretical concern regarding a rAd
vaccine is the possibility that preexisting immunity to natural
Ad5 infection, occurring in up to 50% of the U.S. population,
may affect vaccine efﬁcacy. Recent preliminary results from
HIV vaccine trials suggest that antigen-speciﬁc immune
responses can be readily elicited by rAd5 vectors even in
study participants with prior immunity to adenovirus type 5,
especially when vaccine doses higher than 10
9 are used
(unpublished data). Given that Ebola GP is more immuno-
genic than HIV Env, we would expect that signiﬁcant immune
responses can be generated to the present vaccine; future
clinical trials will resolve this question. In addition, DNA
priming can be used prior to rAd boost to overcome Ad
immunity and has also been shown to be effective in
preventing Ebola infection [2]. In case Ad5 immunity should
Figure 5. Comparative Efficacy of Wild-Type and Point Mutant
Glycoprotein Vaccines against Lethal Ebola Virus Challenge
(A) Kaplan-Meier survivalcurve ofmacaques:Immunization andchallenge
were performed with the Kikwit strain ebolavirus as in Figure 2A.
(B) Immune responses in immunized animals. Left and middle graphs:
Intracellular flow cytometry was performed to quantify TNF-a production
from Ebola-specific CD4þ or CD8þ lymphocytes, respectively, from
animals immunized as indicated. Immune responses were measured at
3 wk postimmunization. Circles, diamonds, and squares indicate
responses for individual animals. Horizontal line indicates average of
individual responses in the immunization group. Results represent the
percent cytokine positive in the gated lymphocyte group, and back-
ground stimulation (DMSO alone) has been subtracted from each
sample. ELISA titers of Ebola GP-specific antibodies in sera of vaccinated
animals collected at week 3 postimmunization (right graph). ELISA
results represent endpoint dilution titers determined by optical density
as described in Methods.
DOI: 10.1371/journal.pmed.0030177.g005
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involving Ad35 and other exotic serotypes, are under
development. Preexisting immunity to Ad35 is quite low
(;10%–15%) worldwide [26], and the same principles
reported in this paper would apply to the development of
such vaccine candidates.
Immunization with 10
10 rAd particles of E71D(Z)þE71D(S/
G) was effective against infectious challenge with ZEBOV.
These data provide evidence that protection does not require
the inclusion of the NP gene in the vaccine, and document
that protective immunity can be conferred by responses to
the GP antigen alone. Indeed, diminished survival was
observed only in vaccine groups containing this gene, raising
the possibility that under some conditions inclusion of NP
may dilute protective immune responses. However, the
signiﬁcance of this result is limited by the relatively small
animal numbers used here. It is noteworthy that elimination
of NP from the vaccine and dose reductions to 10
10 rAd
particles do not diminish protection, and simplify the vaccine
for future development in human trials. A ﬁrst-generation
Ebola DNA vaccine is currently under evaluation in phase I
clinical studies, and the rAd component is currently being
manufactured as a clinical grade preparation that is under-
going safety studies and will be tested in Phase I trials
pending regulatory approvals. After the completion of initial
studies testing individual DNA and rAd vaccine components,
these candidates will be evaluated in prime boost combina-
tion. Vaccine safety and immunogenicity relative to the
nonhuman primate challenge model will guide assessments
regarding its utility as a preventive vaccine in humans.
Supporting Information
Alternative Language Abstract S1. Translation of the Abstract into
French
Found at DOI: 10.1371/journal.pmed.0030177.sd001 (23 KB DOC).
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Background. Humans who get infected with Ebola virus develop an
illness called Ebola hemorrhagic fever (EHV), which is one of the most
deadly viral diseases known; 50%–90% of all ill patients die, and there is
no available treatment for EHV. Scientists think that the occasional
outbreaks of the disease occur because the virus ‘‘jumps’’ from an
infected animal to a person (a rare event) and then is transmitted
between people by direct contact with infected blood or other body
fluids or parts. Several strains or variants of the Ebola virus exist. Most
outbreaks have been caused either by the Zaire strain or by the Sudan/
Gulu strain (so-called because that is where the particular virus was first
isolated). Scientists are working on a vaccine against Ebola that could be
given to people before they get infected and then protect them when
they come in contact with the virus. A number of candidate vaccines
have been developed and tested in animals.
Why Was This Study Done? The researchers who did this study are
workingon a vaccinethat consists of two particular parts of the virus.One
part iscalled GP(whichstands forglycoprotein)andis fromtheoutercoat
of the virus; the other, NP (nucleoprotein), is from its inside. Without the
rest of the virus, GP and NP cannot cause EBV. However, the hope is that
giving these parts of the virus to an individual can educate their immune
system to build a response against GP and NP, which would then
recognize the virus should the vaccinated person become infected with
the whole virus, and destroy it before it can cause disease. To get the GP
and NP parts into the body so that they can cause a strong immune
response (which is what effective vaccines do), the researchers used a
manmade version of another, harmless virus called recombinant
adenovirus 5 (or rAd5) to carry the NP and GP. The researchers have
shown previously that this strategy for introducing a vaccine works in
animals. The vaccine—i.e., the combination of the rAd5 virus and the two
Ebola virus parts—can protect animals against subsequent infection with
real Ebola virus that would otherwise kill them. However, during these
earlierstudies,theresearchershadnoticedthattheGPpart,whenpresent
at high levels, seemed to make human cells sick. They had not seen any
similar problems in the experimental animals, but to be on the safe side
they decided to see whether they could change the GP part so that it
would still be effective as a vaccine but no longer make human cells sick.
What Did the Researchers Do and Find? They changed the GP part of
the vaccine in different ways so that it would no longer make human cells
sick and then tested whether the resulting vaccines (combined with the
original NP part and the Ad5 virus) could still protect monkeys from EHF
after they were infected with Ebola virus. They found that some of the
new GP versions made the vaccine less effective, but others did what they
had hoped for; namely, they gave the same level of protection as when
the original GP part was present. While doing these experiments, the
researchers also found that the NP component seemed unnecessary and
in some cases even weakened the vaccine’s effect.
What Do These Findings Mean? The researchers have now developed a
simplified vaccine against Ebola virus that is effective in monkeys. This
vaccineconsistsofonlyamodifiedGPcomponent(whichis welltolerated
by human cells even at high concentrations) and the rAd5 component.
This vaccine is not the only candidate currently being developed against
Ebola,butitseemslikelythatitisoneofafewthatwillbetestedinhuman
volunteers in the near future. The initial clinical trials will test whether the
vaccineissafeinhumans,andwhetheritcancausetheimmunesystemto
produce an immune response that is specific for the Ebola virus.
Assumingthat the outcomes of these trials are positive, the next question
iswhetherthevaccinecanprotecthumansagainstEboladisease.Because
Ebola is so dangerous and outbreaks are relatively rare, the vaccine will
likely be tested only during an actual outbreak. At that time, an
experimental vaccine might be given to people at immediate risk of
becoming infected, especially health-care workers who, because they
take care of infected patients, are themselves at very high risk of
becoming infected. In addition to trials in humans, the scientists will also
explore whether this vaccine, which was developed based on the GP
component of the Zaire strain, can protect monkeys against infections
with other strains of the Ebola virus.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030177.
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